JP2005521639A5 - - Google Patents

Download PDF

Info

Publication number
JP2005521639A5
JP2005521639A5 JP2003543536A JP2003543536A JP2005521639A5 JP 2005521639 A5 JP2005521639 A5 JP 2005521639A5 JP 2003543536 A JP2003543536 A JP 2003543536A JP 2003543536 A JP2003543536 A JP 2003543536A JP 2005521639 A5 JP2005521639 A5 JP 2005521639A5
Authority
JP
Japan
Prior art keywords
cyanomethyl
trans
cyclohexanecarboxamide
methyl
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003543536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521639A (ja
JP4343690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/036352 external-priority patent/WO2003041649A2/en
Publication of JP2005521639A publication Critical patent/JP2005521639A/ja
Publication of JP2005521639A5 publication Critical patent/JP2005521639A5/ja
Application granted granted Critical
Publication of JP4343690B2 publication Critical patent/JP4343690B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2003543536A 2001-11-13 2002-11-13 プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体 Expired - Fee Related JP4343690B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35131601P 2001-11-13 2001-11-13
PCT/US2002/036352 WO2003041649A2 (en) 2001-11-13 2002-11-13 Cyanoalkylamino derivatives as protease inhibitors

Publications (3)

Publication Number Publication Date
JP2005521639A JP2005521639A (ja) 2005-07-21
JP2005521639A5 true JP2005521639A5 (enExample) 2009-03-26
JP4343690B2 JP4343690B2 (ja) 2009-10-14

Family

ID=23380408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003543536A Expired - Fee Related JP4343690B2 (ja) 2001-11-13 2002-11-13 プロテアーゼ阻害薬としてのシアノアルキルアミノ誘導体

Country Status (8)

Country Link
US (1) US7371747B2 (enExample)
EP (1) EP1446115B1 (enExample)
JP (1) JP4343690B2 (enExample)
AT (1) ATE387197T1 (enExample)
AU (1) AU2002352663B2 (enExample)
CA (1) CA2466115A1 (enExample)
DE (1) DE60225316T2 (enExample)
WO (1) WO2003041649A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759428B2 (en) 2001-12-04 2004-07-06 Roche Palo Alto Llc Indole nitriles
AU2002352126A1 (en) 2001-12-04 2003-06-17 F. Hoffmann-La Roche Ag Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
DK1482924T3 (da) * 2002-03-05 2008-09-29 Merck Frosst Canada Ltd Cathepsin-cystein-protease-inhibotorer
AU2003247425B2 (en) 2002-05-22 2007-03-08 Amgen Inc. Amino-pyridine, -pyridine and pyridazine derivatives for use as vanilloid receptor ligands for the treatment of pain
AU2003264047B2 (en) 2002-08-08 2008-06-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
WO2004108661A1 (en) * 2003-06-04 2004-12-16 Axys Pharmaceuticals Amidino compounds as cysteine protease inhibitors
WO2005000800A1 (en) * 2003-06-30 2005-01-06 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
AR045728A1 (es) * 2003-07-21 2005-11-09 Novartis Ag Composiciones de un inhibidor de catepsina k y un bifosfonato en el tratamiento de metastasis osea, crecimiento de tumor y perdida osea inducida por tumor
CA2535359A1 (en) * 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
MXPA05012129A (es) * 2003-09-18 2006-02-08 Axys Pharm Inc Haloalquilo que contiene compuestos como inhibidores de la proteasa de cisteina.
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
AU2005212438A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AR055283A1 (es) * 2004-11-23 2007-08-15 Merck Frosst Canada Ltd Inhibidores de cisteinproteasa de catepsina
JP5154944B2 (ja) * 2004-12-02 2013-02-27 ビロベイ,インコーポレイティド システインプロテアーゼインヒビターとしてのスルホンアミド含有化合物
US7301022B2 (en) 2005-02-15 2007-11-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2006227254B2 (en) * 2005-03-21 2011-09-01 Quest Diagnostics Investments Llc Alpha ketoamide compounds as cysteine protease inhibitors
CA2602112A1 (en) * 2005-03-22 2006-09-28 Celera Genomics Sulfonyl containing compounds as cysteine protease inhibitors
EP1902031B1 (en) * 2005-07-06 2012-04-11 Merck Canada Inc. Cathepsin cysteine protease inhibitors
MX2009003563A (es) * 2006-10-04 2009-04-15 Virobay Inc Compuestos que contienen di-fluoro como inhibidores de proteasa de cisteina.
US7893112B2 (en) 2006-10-04 2011-02-22 Virobay, Inc. Di-fluoro containing compounds as cysteine protease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
JP5587790B2 (ja) 2008-01-09 2014-09-10 アミュラ セラピューティクス リミティド 化合物
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
CA2729965A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Fused heterocyclyc inhibitor compounds
CA2729909A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Imidazolyl pyrimidine inhibitor compounds
CA2728228A1 (en) 2008-07-14 2010-01-21 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
US8088771B2 (en) 2008-07-28 2012-01-03 Gilead Sciences, Inc. Cycloalkylidene and heterocycloalkylidene inhibitor compounds
US8258316B2 (en) 2009-06-08 2012-09-04 Gilead Sciences, Inc. Alkanoylamino benzamide aniline HDAC inhibitor compounds
US8283357B2 (en) 2009-06-08 2012-10-09 Gilead Sciences, Inc. Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
US8324417B2 (en) * 2009-08-19 2012-12-04 Virobay, Inc. Process for the preparation of (S)-2-amino-5-cyclopropyl-4,4-difluoropentanoic acid and alkyl esters and acid salts thereof
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20130056244A (ko) 2010-04-22 2013-05-29 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
WO2013157022A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
HK1220406A1 (zh) * 2013-03-14 2017-05-05 Chdi Foundation, Inc. 组蛋白去乙酰酶抑制剂及组合物
CN103275034B (zh) * 2013-04-16 2015-07-08 南京工业大学 一类小分子cathepsin D抑制剂的制备方法
KR102447581B1 (ko) 2014-04-15 2022-09-28 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막전도 조절자 매개 질환 치료용 약제학적 조성물
TWI775313B (zh) 2020-02-18 2022-08-21 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
EP4106876B1 (en) 2020-02-18 2025-09-17 Gilead Sciences, Inc. Antiviral compounds
EP4323362B1 (en) 2021-04-16 2025-05-07 Gilead Sciences, Inc. Methods of preparing carbanucleosides using amides
JP7719954B2 (ja) 2021-08-18 2025-08-06 ギリアード サイエンシーズ, インコーポレイテッド リン脂質化合物並びにその製造方法及び使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313847A3 (en) * 1987-10-01 1989-11-29 G.D. Searle & Co. Non-peptidyl alpha-succinamidoacyl aminodiols as anti-hypertensive agents
JP2002539191A (ja) * 1999-03-15 2002-11-19 アクシス・ファーマシューティカルズ・インコーポレイテッド プロテアーゼ阻害剤としての新規化合物及び組成物

Similar Documents

Publication Publication Date Title
JP2005521639A5 (enExample)
US10214477B2 (en) (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
JP2010504342A5 (enExample)
US20040147745A1 (en) Novel compounds and compositions as protease inhibitors
US7371747B2 (en) Cyanoalkylamino derivatives as protease inhibitors
RU2419624C2 (ru) Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2
AR048306A1 (es) Derivados de acidos carboxilicos aromaticos con capacidad moduladora de los niveles de insulina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos metabolicos que responden a la regulacion de gpr40
RU2012129737A (ru) Замещенные бензамидные производные
RU2007119427A (ru) Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе
NZ600084A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20040014796A1 (en) Novel compounds and compositions as cathepsin S inhititors
US20100317582A1 (en) Novel cyclic hydrocarbon compounds for the treatment of diseases
US20090143592A1 (en) Glucagon Antagonists/Inverse Agonists
HRP20140970T1 (hr) Spoj azolkarboksamida ili njegova sol
CA2482346A1 (en) Substituted phenylacetamides and their use as glucokinase activators
NZ332478A (en) Use of collagenase-3 selective inhibitors for treating joint diseases
JP2004504301A5 (enExample)
CA2647819A1 (en) Phenylcyclohexyl derivatives as dgat1 inhibitors
WO2003075836A2 (en) Cathepsin cysteine protease inhibitors
CA2300051A1 (en) Amide derivatives for the treatment of diseases mediated by cytokines
RU2015113746A (ru) Замещенные сульфонамиды
CA2433520A1 (en) Novel compounds and compositions as cathepsin inhibitors
CA2540196A1 (en) Pyridine derivatives and use thereof as urotensin ii antagonists
US8507493B2 (en) Amide and amidine derivatives and uses thereof
JP2023062064A5 (enExample)